Combining Forces to Combat Infectious Diseases

Because the threat of infectious diseases can cause widespread fear in a community, these diseases receive much public attention. Collaborations that bring together industry, academia, regulators, and the public can lead to improved and accelerated drug development. The collaborations must be ground...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2014-08, Vol.96 (2), p.123-126
Main Author: Reynolds, K S
Format: Article
Language:English
Subjects:
Antiviral Agents - therapeutic use
Biomarkers - metabolism
Clinical Trials as Topic
Drug Resistance, Microbial
Hepatitis C - diagnosis
Hepatitis C - drug therapy
Hepatitis C - metabolism
HIV Infections - diagnosis
HIV Infections - drug therapy
HIV Infections - metabolism
Humans
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Because the threat of infectious diseases can cause widespread fear in a community, these diseases receive much public attention. Collaborations that bring together industry, academia, regulators, and the public can lead to improved and accelerated drug development. The collaborations must be grounded in strong science and expertise in clinical trials. Development of drugs to treat infections caused by resistant bacteria, drugs to treat hepatitis C virus (HCV), and drugs to prevent HIV is taking advantage of these collaborations. Clinical Pharmacology & Therapeutics (2014); 96 2, 123–126. doi:10.1038/clpt.2014.119
ISSN:0009-9236
1532-6535
DOI:10.1038/clpt.2014.119